UNOREADY Trademark

Trademark Overview

On Tuesday, March 16, 2021, a trademark application was filed for UNOREADY with the United States Patent and Trademark Office. The USPTO has given the UNOREADY trademark a serial number of 90581994. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Tuesday, July 23, 2024. This trademark is owned by Novartis AG. The UNOREADY trademark is filed in the Pharmaceutical Products category with the following description:

Autoinjectors sold pre-filled with pharmaceutical preparations for the treatment of inflammatory disorders, plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, active ankylosing spondylitis, rheumatoid arthritis, central nervous system disorders, multiple sclerosis
unoready

General Information

Serial Number90581994
Word MarkUNOREADY
Filing DateTuesday, March 16, 2021
Status734 - FIFTH EXTENSION - GRANTED
Status DateTuesday, July 23, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 30, 2021

Trademark Statements

Goods and ServicesAutoinjectors sold pre-filled with pharmaceutical preparations for the treatment of inflammatory disorders, plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, active ankylosing spondylitis, rheumatoid arthritis, central nervous system disorders, multiple sclerosis
Translation of Words in MarkThe wording UNOREADY has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, June 16, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNovartis AG
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBasel 4002
CH
Party NameNovartis AG
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBasel 4002
CH

Trademark Events

Event DateEvent Description
Wednesday, June 16, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, March 19, 2021NEW APPLICATION ENTERED
Thursday, October 21, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, October 16, 2021ASSIGNED TO EXAMINER
Wednesday, November 10, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 30, 2021PUBLISHED FOR OPPOSITION
Tuesday, November 30, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 25, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, July 20, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 17, 2023SOU TEAS EXTENSION RECEIVED
Monday, July 18, 2022SOU TEAS EXTENSION RECEIVED
Monday, July 18, 2022SOU EXTENSION 1 FILED
Monday, July 18, 2022SOU EXTENSION 1 GRANTED
Tuesday, January 17, 2023SOU EXTENSION 2 GRANTED
Tuesday, January 17, 2023SOU EXTENSION 2 FILED
Tuesday, July 23, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, July 23, 2024SOU EXTENSION 5 GRANTED
Tuesday, July 23, 2024SOU EXTENSION 5 FILED
Wednesday, July 24, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 24, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 19, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 18, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, July 18, 2023SOU EXTENSION 3 FILED
Tuesday, July 18, 2023SOU EXTENSION 3 GRANTED
Thursday, July 20, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 22, 2024SOU TEAS EXTENSION RECEIVED
Monday, January 22, 2024SOU EXTENSION 4 FILED
Monday, January 22, 2024SOU EXTENSION 4 GRANTED

Related Keywords

unoready arthritis disorders rheumatoid spondylitis ankylosing active central nervous sclerosis multiple